Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Prospective, Multi-center, Phase I/II Clinical Study

This study evaluates the safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase II dose (RP2D) of Glecirasib in combination with Ivonescimab in patients with previously untreated, KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥1%. The study includes a Phase I 3+3 dose-escalation stage followed by a Phase II Simon two-stage design to assess preliminary antitumor efficacy.

开始日期2026-03-01

申办/合作机构

中国医学科学院肿瘤医院

NCT07164170

/ Not yet recruiting临床2期

An Open-label Phase II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ABSK043 in Combination With Glecirasib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring a KRAS G12C Mutation

This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.

开始日期2025-10-25

申办/合作机构

上海和誉生物医药科技有限公司

NCT06838338

/ Active, not recruiting临床1期IIT

A Phase Ib, Open Lable, Clinical Trial of JAB-21822 Combined With Second Line Chemotherapy and Bevacizumab for Metastatic Colorectal Cancer With KRAS G12C Mutation

KRAS is a common genetic mutation in tumors, and CRC is one of the tumors with a high KRAS mutation rate. The anti-tumor activity of KRAS G12C inhibitors combined with anti-EGFR anti-bodies have been proven in patients with advanced colorectal cancer, and one of them was approved for patients who have previously received standard treatment. However, Chinese patients still do not have access to these drugs. This study is to determine the efficacy and safety of KRAS G12C inhibitor JAB-21822 in combination with the second-line standard chemotherapy and bevacizumab in advanced colorectal cancer failed to standard therapy in Chinese population.

开始日期2025-03-20

申办/合作机构-

100 项与枸橼酸格来雷塞相关的临床结果

登录后查看更多信息

100 项与枸橼酸格来雷塞相关的转化医学

登录后查看更多信息

100 项与枸橼酸格来雷塞相关的专利（医药）

登录后查看更多信息

项与枸橼酸格来雷塞相关的文献（医药）

2026-02-01·Lancet Respiratory Medicine

Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial

Article

作者: Yu, Yan ; Duan, Jianchun ; Xing, Ligang ; Ye, Feng ; Li, Xiaoyan ; Wang-Gillam, Andrea ; Liu, Zhe ; Cao, Baoshan ; Zhao, Yanqiu ; Xu, Jiachen ; Tang, Kejing ; Bi, Chao ; Zhong, Jia ; Wu, Lin ; Jin, Bo ; Wan, Rui ; Liu, Lian ; Song, Qibin ; Fang, Xuefeng ; Dong, Xiaorong ; Zhao, Jun ; Li, Xingya ; Chen, Jiayan ; Pang, Jiaohui ; Chang, Jianhua ; Wang, Zhijie ; Shi, Jianhua ; Wang, Jie ; Zhuang, Wu ; Fei, Kailun ; Pan, Yueyin ; Fang, Jian ; Sun, Boyang ; Chu, Qian ; Zhang, Li ; Pan, Pinhua ; Ding, Yuli ; Bai, Chunmei ; Shao, Yang

BACKGROUND:

Monotherapy with KRAS^G12C (ie, KRAS Gly12Cys) inhibitors has emerged as a mainstream treatment for patients with KRAS^G12C -mutated non-small-cell lung cancer (NSCLC). Synergistic effects have been observed with the combination of a KRAS^G12C inhibitor and a SHP2 inhibitor in multiple xenograft models. We aimed to evaluate the safety and efficacy of the KRAS^G12C inhibitor glecirasib combined with the SHP2 inhibitor sitneprotafib (JAB-3312; Jacobio Pharmaceuticals, Beijing, China) in patients with KRAS^G12C -mutated solid tumours.

METHODS:

We conducted an open-label, multicentre, single-arm, phase 1/2a trial at 26 hospitals across China. Patients (aged ≥18 years) with locally advanced or metastatic solid tumours harbouring a KRAS^G12C mutation, an Eastern Cooperative Oncology Group performance status score of 0-1, and measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST; version 1.1) were eligible for inclusion in both phases. Patients received oral glecirasib (400 mg or 800 mg once daily) in combination with oral sitneprotafib (2 mg or 3 mg once daily) in seven cohorts evaluating various dose levels and schedules of the two drugs. In phase 1, the primary endpoint was safety assessed by investigators according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0) from first treatment dose to 30 days after the last dose of both agents. In phase 2a, the primary endpoint was objective response rate (ORR) between baseline and disease progression or initiation of anticancer therapy, whichever occurred first, based on the comprehensive assessment of all tumour evaluations by investigators following RECIST (version 1.1). All patients who received at least one dose of combination therapy were included in the safety and efficacy analyses. This trial is registered with ClinicalTrials.gov (NCT05288205) and is currently recruiting.

FINDINGS:

Between May 7, 2022, and Aug 20, 2024, a total of 194 patients with advanced solid tumours were enrolled, of whom 171 (88%) had NSCLC (50 [29%] in phase 1 and 121 [71%] in phase 2a). Median participant age was 65 years (IQR 59-70); 140 (82%) were men and 31 (18%) were women. At data cutoff on Aug 20, 2024, the median follow-up duration was 14·5 months (IQR 11·9-17·1), and 106 (62%) patients had discontinued treatment. Phase 1 concluded with one dose-limiting toxicity (DLT; grade 3 pneumonitis) at the highest dose level (glecirasib 800 mg plus sitneprotafib 3 mg once daily, 1 week on and 1 week off); no DLTs were observed at other dose levels. Across phase 1 and 2a, 167 patients (98%) had at least one treatment-related adverse event, which were grade 3-4 in 78 (46%) patients. The most common treatment-related adverse events (occurring in ≥20% of all 171 patients) were anaemia (105 [61%]), hypertriglyceridaemia (103 [60%]), increased aspartate aminotransferase (95 [56%]), increased alanine aminotransferase (83 [49%]), increased blood bilirubin (78 [46%]), oedema (62 [36%]), increased blood creatine phosphokinase (60 [35%]), neutropenia (54 [32%]), decreased white blood cell count (50 [29%]), and increased bodyweight (44 [26%]). Three (2%) patients discontinued glecirasib and sitneprotafib due to treatment-related adverse events. No grade 5 treatment-related adverse event was reported. The ORR was 71% (72 patients [95% CI 61-79]) in the subgroup of 102 patients with previously untreated NSCLC; 49% (19 patients [32-65]) in the 39 patients previously treated with systemic therapy but naive to KRAS^G12C inhibitors; and 10% (three patients [2-27]) in the 30 patients previously treated with KRAS^G12C inhibitor therapy.

INTERPRETATION:

Glecirasib combined with sitneprotafib showed promising efficacy and manageable safety in patients with advanced KRAS^G12C -mutated NSCLC, particularly among those who had not received previous treatment. These findings support the evaluation of this combination in a phase 3 trial comparing this chemotherapy-free regimen to current standard of care in this patient group.

FUNDING:

Jacobio Pharmaceuticals.

TRANSLATION:

For the Chinese translation of the abstract see Supplementary Materials section.

2026-02-01·The Lancet Gastroenterology & Hepatology

Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials

Article

作者: Cao, Baoshan ; Li, Xiaoyan ; Ba, Yi ; Shi, Huaqiu ; Shen, Lin ; Sun, Xin ; Wang-Gillam, Andrea ; Liu, Lian ; Li, Wenhua ; Lu, Shuang ; Yin, Xianli ; Liang, Rong ; Hu, Changlu ; Li, Yongsheng ; Li, Zhen ; Wang, Zhenghang ; Zhang, Yanqiao ; Li, Jian ; Liang, Xinjun ; Luo, Suxia ; Li, Zhihua ; Xiong, Jianping ; Li, Xingya ; Song, Zhengbo ; Zhu, Liangjun ; Xia, Guohao ; Bai, Chunmei ; Zhong, Diansheng ; Fu, Qihan ; Huang, Jing ; Huang, Chenghui ; An, Guangyu ; Ding, Yuli ; Wang, Zhen ; Wang, Feng ; Pan, Wenhui ; Rao, Zhiyue ; Gu, Yanhong

BACKGROUND:

KRAS^G12C mutations are present in around 4% of patients with colorectal cancer and are associated with lower treatment response rates and overall survival. EGFR signalling has been identified as a primary mechanism of resistance to KRAS^G12C inhibitors. We aimed to evaluate the efficacy and safety of a novel, covalent, small molecule KRAS^G12C inhibitor, glecirasib (JAB-21822), as monotherapy or in combination with the anti-EGFR cetuximab, in patients with KRAS^G12C-mutated colorectal cancer.

METHODS:

JAB-21822-1002 was an open-label, non-randomised, dose escalation (phase 1) and expansion (phase 2a) trial evaluating glecirasib monotherapy in KRAS^G12C-mutated solid tumours. JAB-21822-1007 was an open-label, non-randomised, dose escalation (phase 1b) and expansion (phase 2) study evaluating glecirasib plus cetuximab in KRAS^G12C-mutated colorectal, small intestine, and appendiceal cancer. Adult participants (aged ≥18 years) were recruited in China from 17 hospitals for the monotherapy trial and 16 hospitals for the combination trial. Here, we report only on patients with colorectal cancer treated with oral glecirasib at the recommended phase 2 dose (800 mg once daily in 21-day treatment cycles [until disease progression, intolerable toxicity, investigator's discretion, or withdrawal of consent]), pooling phase 1 and 2 data together. In the combination trial, cetuximab was administered intravenously with an initial loading dose of 400 mg/m² in the first week, followed by 250 mg/m² every week or 500 mg/m² every 2 weeks. For this analysis, key eligibility criteria were histologically or cytologically confirmed locally advanced or metastatic colorectal cancer with KRAS^G12C mutation; Eastern Cooperative Oncology Group performance status of 0 or 1; and at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST). For phase 1 of both trials, patients must not have responded to, were not suitable for, or refused standard of care. For phase 2 of both trials, patients must have received at least first-line standard of care and had disease progression or intolerance. Primary endpoints for the monotherapy trial were safety (treatment-emergent adverse events, serious adverse events, treatment-related adverse events, dose-limiting toxicity, and clinically significant changes in vital signs, physical examination, and electrocardiography, and clinically significant unexpected laboratory values of grade ≥3) for phase 1 and objective response rate (complete and partial response) for phase 2a. Primary endpoints for the combination trial were dose-limiting toxicities, maximum tolerated dose, and recommended phase 2 dose for phase 1b and objective response rate for phase 2. The full analysis set was defined as patients with at least one measurable lesion at baseline who received at least one dose of glecirasib in the monotherapy trial, or at least one dose of glecirasib plus cetuximab in the combination trial. The safety analysis set was defined as patients who received at least one dose of glecirasib in the monotherapy trial, or at least one dose of glecirasib or cetuximab in the combination trial. The trials are registered with ClinicalTrials.gov (NCT05009329 and NCT05194995), and are active but no longer recruiting.

FINDINGS:

Between Oct 12, 2021, and Dec 4, 2023, 44 patients with colorectal cancer (27 male and 17 female) in the monotherapy trial received glecirasib 800 mg once daily and comprised the full analysis and safety analysis sets. Between Feb 17, 2022, and Feb 28, 2023, 47 patients with colorectal cancer (22 male and 25 female) in the combination trial received glecirasib 800 mg once daily plus cetuximab and comprised the safety analysis set. One patient was excluded from the full analysis set as they received glecirasib only. Data cutoff was June 30, 2024. Median follow-up was 21·9 months (IQR 20·0-25·5) in the monotherapy trial and 18·7 months (15·9-20·6) in the combination trial. In the monotherapy trial phase 1, 15 patients with colorectal cancer were enrolled. No dose-limiting toxicities, unexpected grade 3 or worse laboratory values, or changes in vital signs, physical examinations, or electrocardiography were observed. 15 (100%) patients had treatment-emergent adverse events (n=8 [53%] grade ≥3), 13 (87%) of 15 reported treatment-related adverse events (n=4 (27%) grade ≥3); five (33%) of 15 patients had serious treatment-emergent adverse events, none were treatment-related. In the combination trial phase 1b, six patients with colorectal cancer were enrolled. No dose-limiting toxicities were observed and the maximum tolerated dose was not reached. The recommended phase 2 dose was chosen as glecirasib 800 mg once daily. Objective response rate was 23% (95% CI 11-38; ten of 44 patients [ten partial responses]) in the monotherapy trial and 50% (35-65; 23 of 46 patients [23 partial responses]) in the combination trial. The most common treatment-related adverse events were anaemia (24 [55%]), blood bilirubin increased (23 [52%]), and conjugated bilirubin increased (17 [39%]) in the monotherapy trial, and rash (39 [83%]), blood bilirubin increased (29 [62%]), conjugated bilirubin increased (17 [36%]), alanine aminotransferase increased (16 [34%]), and anaemia (15 [32%]) in the combination trial. The incidence of grade 3 or 4 treatment-related adverse events was 20% (nine of 44) in the monotherapy trial and 19% (nine of 47) in the combination trial. Two (5%) of 44 patients in the monotherapy trial (febrile neutropenia, n=2) and four (9%) of 47 patients in the combination trial (interstitial lung disease [n=1], pleural effusion and pericardial effusion [n=1], pyrexia [n=1], and rash [n=1]) reported serious treatment-related adverse events. No treatment-related deaths were observed in either trial.

INTERPRETATION:

Glecirasib monotherapy and its combination with cetuximab represent potential treatment options for patients with advanced, refractory colorectal cancer harbouring KRAS^G12C mutations. The promising efficacy and safety support further exploration of glecirasib-based combinations in earlier lines of treatment.

FUNDING:

Jacobio.

TRANSLATION:

For the Mandarin translation of the abstract see Supplementary Materials section.

2025-11-01·Cancer Communications

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Article

作者: Jon Zugazagoitia ; Ayala Hubert ; Jian Li ; Diansheng Zhong ; Wenming Wu ; Ting Deng ; Julia Martínez-Pérez ; Zhengbo Song ; Zhiyue Rao ; Ligang Xing ; Xueqin Chen ; Jian Zhang ; Lian Liu ; Zhihua Li ; Guohao Xia ; Andrea Wang-Gillam ; Guilan Wen ; Antonio Calles Blanco ; Xinghu Liu ; Jing Huang ; Yanqiu Zhao ; Lin Wu ; Yanhong Gu ; Yu Yao ; Yongsheng Wang ; Yuli Ding ; Sumei Liu ; Yongsheng Li ; Xingya Li ; Chunmei Bai ; Kuirong Jiang ; Lin Shen

Abstract:

Background:

Glecirasib, an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine‐to‐cysteine substitution at codon 12 ( KRAS G12C), has exhibited clinical activity in non‐small‐cell lung cancer (NSCLC) and colorectal cancer (CRC). Here, we investigated the efficacy and safety of glecirasib in patients with pancreatic ductal adenocarcinoma (PDAC) and other solid tumors (excluding NSCLC and CRC) that rarely harbor the KRAS G12C mutation but for which effective treatment options remain limited.

Methods:

We conducted and analyzed two open‐label, phase I/II trials in adult patients with KRAS G12C mutant solid tumors, in which glecirasib was administered orally. The two trials had similar eligibility criteria and endpoints but differed in the regions of patient recruitment. We performed a pooled analysis of all patients, excluding NSCLC and CRC, from both trials. The primary endpoint in the pooled population was objective response rate (ORR). Efficacy and safety were assessed in patients who received at least one dose of glecirasib.

Results:

As of June 30, 2024, the pooled analysis included 54 patients who were treated with glecirasib: 32 PDACs, 8 biliary tract cancers (BTCs), 4 small intestinal cancers, 3 gastric cancers, 2 appendiceal cancers, and 5 other tumors. At baseline, 24 received ≥ two prior lines of systemic therapy. Of the 53 efficacy‐evaluable patients, the confirmed ORR was 50.9% (95% confidence interval [CI], 36.8%‐64.9%), with an ORR of 46.9% (95% CI, 29.1%‐65.3%) in PDAC patients. Among other solid tumors, ORR was 71.4% (5/7) in BTC, 100% (4/4) in small intestinal cancer, and 66.7% (2/3) in gastric cancer. Median progression‐free survival and median overall survival were 6.9 and 10.8 months, respectively, in the overall population, and 5.5 and 10.8 months, respectively, in patients with PDAC. Treatment‐related adverse events (TRAEs) of any grade occurred in 94.4% patients, with grade ≥ 3 TRAEs in 27.8%. No fatal TRAEs or TRAEs leading to treatment discontinuation occurred.

Conclusions:

Glecirasib showed promising efficacy and was well tolerated in patients with PDAC and other advanced solid tumors (beyond NSCLC and CRC), warranting further expedited clinical development in this patient population.

Trial registration:

ClinicalTrials.gov identifier: NCT05009329 and NCT05002270.

574

项与枸橼酸格来雷塞相关的新闻（医药）

2026-03-30

·今日头条

告别天价抗癌药！国产药量产，普通人也能治得起

别再怕癌症了！国产杀癌药量产，让“天价救命药”走进寻常百姓家 2026年3月28日，广东东莞松山湖科学城传来足以载入中国医疗史册的重磅消息：中国科学院高能物理研究所联合中国同辐原子高科，依托中国散裂中子源这一国之重器，正式实现医用级阿尔法同位素（锕-225、镭-223、铅-212/铋-212）居里级量产，纯度高达99%以上。这不是实验室里的阶段性成果，而是实打实的产业化落地——当天双方签署战略合作协议，标志着中国彻底打破欧美在高端杀癌核药领域长达20年的绝对垄断，从“100%依赖进口”直接跃升至“自主可控、批量供应”。与此同时，国产CAR-T、靶向药、ADC药物等创新抗癌药也迎来集中量产与降价潮：曾经一针120万的CAR-T细胞治疗药，国产版定价降至20-25万，降幅超80%；肺癌、乳腺癌、前列腺癌等高发癌种的国产靶向药，通过集采与医保谈判，价格从数万元降至数千元，医保报销后个人自付仅数百元。从“天价药望而却步”到“平民价触手可及”，国产杀癌药的量产浪潮，正在彻底改写中国癌症治疗的格局，让千万家庭不再因癌致贫、因药绝望。一、核药革命：从30万/针到6万/针，国产“抗癌核弹”批量下线在癌症治疗领域，阿尔法核素靶向治疗被称为“抗癌核弹”——它能精准锁定癌细胞，释放高能量α射线，在微米级范围内摧毁肿瘤组织，对正常细胞损伤极小，是中晚期前列腺癌、神经内分泌瘤、骨转移癌等难治性肿瘤的“终极武器”。但长期以来，这项技术被欧美国家牢牢垄断，我国100%依赖进口，不仅价格高得离谱，还时常面临“断供”风险。此前，进口锕-225每毫居里售价高达30万元，一个常规疗程需要3-5毫居里，仅药费就超百万元，普通家庭根本无力承担。更让人无奈的是，国外供应商时常以“产能不足”为由限制供应，很多晚期患者即便凑齐费用，也买不到药，只能在绝望中等待。而此次国产突破，直接实现了从“毫居里级实验室生产”到“居里级产业化量产”的跨越，产能提升1000倍。目前，我国已具备年产居里级铅-212/铋-212的能力，预计2027年300MeV专用生产线建成后，年产能将达百居里级，可满足近百万患者的用药需求，彻底终结“一药难求”的局面。价格方面，国产化带来的降幅堪称“颠覆性”：原料成本从每毫居里2000元压至900元以下，降幅超50%；跨境冷链运输改为国内配送，运输时间缩短10小时，减少放射性衰减损失，再省30%；叠加规模效应，终端价格预计降至进口药的1/5，30万/针的天价药，未来6万左右就能用上。更重要的是，国产核药已纳入医保谈判范围，报销后患者自付费用将进一步降至2万元以内，真正让“抗癌核弹”走进寻常百姓家。除了阿尔法核药，国产β核素领域也实现全面替代：秦山核电基地建成国内首个医用β核素生产基地，镥-177、碘-131等常用核药实现100%国产，价格较进口药下降40%-60%，覆盖甲状腺癌、神经内分泌瘤等多个癌种。中国核药产业已形成“α+β”双轮驱动、全产业链自主可控的格局，从“跟跑”到“领跑”，彻底摆脱“卡脖子”困境。二、细胞治疗破局：120万→20万，CAR-T从“贵族药”变“平民药” 如果说核药是“抗癌核弹”，那CAR-T细胞治疗就是“抗癌特种兵”——它通过提取患者自身T细胞，在体外进行基因改造、扩增后回输体内，精准识别并杀死癌细胞，是血液肿瘤（淋巴瘤、白血病、多发性骨髓瘤）的“治愈级”疗法。但此前，进口CAR-T药物一针售价高达120万元，被称为“天价救命药”，绝大多数患者只能望药兴叹。 2025年底，国产自主研发的CD19靶向CAR-T药物提交上市申请，2026年3月正式获批上市，定价仅20-25万元，降幅超80%。这款药物拥有完全自主知识产权，从核心技术、细胞培养设备到关键物料，全部实现国产，摆脱了对进口设备与试剂的依赖。同时，企业采用全自动无人化生产系统，产能提升50倍，年产能达9000人份，彻底解决了“产能不足、价格高昂”的痛点。更让人振奋的是，国产CAR-T的疗效不逊于进口药：针对复发难治性B细胞淋巴瘤，总缓解率达95%以上，完全缓解率超80%，2年无病生存率达70%，与进口药数据基本一致。针对多发性骨髓瘤的GC012F双靶点CAR-T疗法，在一线治疗中总缓解率达100%，随访2年半，绝大部分患者保持无病生存状态，为血液肿瘤患者带来了真正的治愈希望。 2026年1月，国产CAR-T正式纳入新版国家医保目录，医保谈判平均降幅超60%，职工医保报销后个人自付仅需5-8万元，城乡居民医保自付8-10万元。对于低保、特困等困难群体，报销比例再上浮10个百分点，且取消年度最高支付限额，让更多血液肿瘤患者用得起、用得上这一“治愈级”疗法。除了CAR-T，国产TIL疗法、NK细胞注射液等创新细胞治疗药也迎来量产突破：GC101 TIL疗法针对耐药肺癌，缓解率超40%，预计2026年底提交上市申请；加强型NK细胞注射液填补了实体瘤免疫治疗空白，价格较传统细胞疗法下降70%，普通家庭也能承担。中国细胞治疗产业正从“单一品种”走向“多品类集群”，从“天价”走向“普惠”。三、靶向药普惠：从数万元/盒到数百元/盒，高发癌种实现“平价治疗” 肺癌、乳腺癌、结直肠癌、肝癌等高发癌种，是我国癌症患者的主要“杀手”，而靶向药是这些癌种的核心治疗药物。长期以来，进口靶向药价格高昂，如吉非替尼（肺癌靶向药）上市初每盒5000元，阿比特龙（前列腺癌靶向药）每月费用1.7万元，很多患者因药费放弃治疗。 2025年，国家药监局批准76款创新药，同比增长58.3%，创历史新高，其中抗肿瘤新药34款，覆盖肺癌、乳腺癌、结直肠癌等十多种高发癌种。2026年1月1日，2025版国家医保目录正式落地，新增114种药品，其中肿瘤用药36种，谈判平均降幅超60%，最高降幅达90%以上。同时，第十批肿瘤药集采中选，平均降幅超60%，氟尿嘧啶注射液低至1.69元/支，哌柏西利胶囊降至118元/盒。以肺癌治疗为例：国产吉非替尼（伊瑞可）上市后，价格从5000元/盒降至1980元/盒，集采后进一步降至498元/盒，医保报销后个人自付仅100-150元。针对KRAS G12C突变的国产靶向药氟泽雷塞、戈来雷塞、格索雷塞，谈判后价格分别降至5790.4元/盒、4000元/盒、2562元/盒，年治疗费用从22.32万元降至约2.08万元（按医保70%报销计算）。乳腺癌治疗同样迎来“平价时代”：国产HER2 ADC药物博度曲妥珠单抗，打破国外垄断，价格较进口药下降70%，医保报销后每月自付仅2000-3000元；国产CDK4/6抑制剂瑞波西利，从晚期后线治疗纳入一线治疗，医保报销后每月自付仅1000元左右。前列腺癌患者的负担也大幅减轻：阿比特龙集采前每月1.7万元，集采后国产药仅700多元，医保报销后个人自付100-200元；国产PSMA放射配体疗法镥[177Lu]特昔维匹肽注射液，价格较进口药下降60%，医保报销后每疗程自付仅3-5万元。从“天价靶向药”到“平价普惠药”，国产创新药+集采+医保谈判的“组合拳”，让高发癌种的治疗费用下降80%-90%，彻底打破了“用药贵、用药难”的壁垒，让普通家庭也能接受规范、有效的抗癌治疗。四、政策护航：医保扩容+商保补充，构建全民抗癌保障网国产杀癌药的量产与降价，离不开国家政策的强力护航。2026年，国家医保局、药监局等部门密集出台政策，从“药品准入、价格调控、报销扩容、基层覆盖”四个维度，构建起全方位的抗癌保障体系，让好药、新药真正惠及每一位患者。（一）医保报销全面扩容，覆盖更广、比例更高 2026年3月，国家医保局发布《关于优化肿瘤免疫治疗药品医保支付范围的通知》，自4月1日起实施：免疫治疗覆盖癌种从8类扩大至12类，新增胃癌、食管癌、宫颈癌、三阴性乳腺癌，国内发病率最高的前六大癌种全部纳入医保。报销比例大幅提升：城镇职工医保从70%提高至85%，城乡居民医保从60%提高至75%；困难群体报销比例再上浮10个百分点，取消年度最高支付限额。同时，多款肿瘤药实现医保适应症扩容：替雷利珠单抗（PD-1）医保报销适应症扩容至14项，覆盖8大高发癌种，实现肺癌从早中期到晚期的全病程医保覆盖；特瑞普利单抗（PD-1）成为唯一覆盖黑色素瘤全治疗线数的PD-1单抗；奥希替尼、阿美替尼等肺癌靶向药，从晚期二线治疗纳入早中期术后辅助治疗，有效降低复发风险。（二）商保创新药目录出台，填补医保保障空白 2026年1月1日，首版《商业健康保险创新药品目录》正式实施，与基本医保形成互补衔接。该目录纳入19种药品，包括CAR-T细胞治疗药、TCE疗法、双特异性抗体等高价创新药，以及儿童罕见病抗癌药。参保人购买商业健康保险后，可对这些医保未覆盖的创新药进行报销，报销比例达50%-70%，进一步减轻患者经济负担。（三）基层医疗覆盖加速，让患者在家门口用上好药为解决“基层缺药、患者跑大城市”的问题，2026年国家卫健委启动“基层肿瘤规范化治疗提升工程”：在全国2000家县级医院建设肿瘤规范化诊疗中心，配备国产靶向药、免疫药、核药等常用抗癌药；开展基层医生肿瘤诊疗培训，提升基层抗癌治疗能力；推进“互联网+肿瘤医疗”，实现远程会诊、线上购药、送药上门，让偏远地区患者在家门口就能用上国产杀癌药。五、产业崛起：从“仿制跟随”到“创新引领”，中国抗癌药走向全球国产杀癌药的量产与普惠，背后是中国医药产业从“仿制跟随”到“创新引领”的华丽转身。近年来，我国持续加大医药研发投入，2025年医药研发投入超3000亿元，同比增长25%，其中抗肿瘤药物研发投入占比超40%。依托“重大新药创制”国家科技专项，我国在靶向药、免疫药、细胞治疗、核药等领域实现全面突破，多款国产抗癌药达到国际领先水平。在研发端，国内药企与科研院所深度合作，构建“产-学-研-用”一体化体系：中科院高能所、中国医学科学院、复旦大学等科研机构，攻克了核药制备、CAR-T基因编辑、ADC药物偶联等核心技术；恒瑞医药、百济神州、齐鲁制药、复星凯特等药企，实现了从研发到产业化的全链条布局，年产创新抗癌药超100种。在生产端，国产抗癌药实现规模化、智能化生产：CAR-T细胞治疗采用全自动无人化生产线，产能提升50倍；核药生产依托散裂中子源、核电基地等国之重器，实现居里级量产；靶向药、ADC药物采用连续化生产工艺，生产成本下降60%，质量稳定性大幅提升。在国际端，国产抗癌药开始走向全球：多款国产靶向药、免疫药通过美国FDA、欧盟EMA认证，进入国际市场；国产核药、CAR-T药物与东南亚、中东、非洲等国家签署合作协议，实现技术输出与药品出口。中国抗癌药产业正从“国内普惠”走向“全球贡献”，为全球癌症患者带来中国方案。六、结语：科技向善，让每一个生命都有被守护的权利从30万/针的核药到6万/针，从120万/针的CAR-T到20万/针，从数万元/盒的靶向药到数百元/盒，国产杀癌药的量产浪潮，是中国医疗科技自主创新的胜利，更是国家“以人民为中心”发展理念的生动实践。它不仅打破了欧美国家的技术垄断与价格霸权，更让千万癌症家庭摆脱了“因癌致贫、因药绝望”的困境，让“癌症不再是绝症，抗癌不再是天价”成为现实。这背后，是科研人员数十年如一日的攻坚克难，是药企勇于创新、敢于担当的产业情怀，是国家政策精准发力、保驾护航的民生温度。从“一药难求”到“批量供应”，从“天价药”到“平民价”，从“基层缺药”到“全域覆盖”，中国癌症治疗正迎来历史性拐点——科技向善，让每一个生命都有被守护的权利，让每一个家庭都能拥抱健康与希望。未来，随着国产抗癌药技术的持续突破、产能的不断扩大、医保覆盖的进一步扩容，癌症治疗将更加普惠、更加精准、更加有效。我们有理由相信，在科技与政策的双重加持下，“别再怕癌症”将不再是一句口号，而是每一位患者都能触手可及的现实。话题讨论 1. 国产杀癌药量产降价，你身边是否有癌症患者因此受益？ 2. 对于医保扩容与商保补充的抗癌保障体系，你还有哪些期待？ 3. 你认为未来国产抗癌药还需在哪些方面发力，才能更好地惠及百姓？

抗体药物偶联物细胞疗法免疫疗法放射疗法上市批准

2026-03-30

·蒲公英资讯

1亿美元到账！加科思与阿斯利康泛KRAS合作进入实质推进阶段

点击蓝字关注我们 2026年3月30日，加科思药业（01167.HK）发布公告称，其非全资附属公司北京加科思新药研发有限公司已就此前与阿斯利康达成的许可与合作协议，收到对方支付的1亿美元首付款。这笔资金已于近日到账，将显著增强公司现金储备，为后续创新肿瘤治疗管线的研发推进提供支持。一笔打破纪录的小分子抗癌药BD交易回顾此次合作的背景，2025年12月，加科思就其自主研发的泛KRAS抑制剂JAB-23E73与阿斯利康达成全球独家许可协议。根据协议条款，阿斯利康获得该产品在中国以外市场的独家开发和商业化权利，而中国市场则由双方共同开发和商业化。这是中国临床阶段小分子抗癌药领域金额最大的对外授权合作，总交易金额达20.15亿美元。具体而言，加科思除了获得1亿美元首付款外，还有资格获得最高约19.15亿美元的开发及商业化里程碑付款，以及在中国以外市场实现的净销售额分级特许权使用费。此次首付款的到账，标志着双方合作从协议签署进入实质推进阶段。 1亿美元落袋对加科思意味着什么这笔1亿美元的资金对加科思的意义不言而喻。根据公司披露的2025年业绩，全年收入为5352.5万元，净亏损1.46亿元。而首付款的到账将直接改善公司现金流状况。截至2025年末，加科思现金及现金等价物及银行授信合计约15.3亿元，公司预计2026年第一季度该余额将超过20亿元，并预计2026年实现扭亏为盈。加科思董事长兼联席首席执行官王印祥博士曾在业绩沟通会上明确表示，来自阿斯利康的1亿美元首付款、来自艾力斯的戈来雷塞片销售分成以及潜在的已授权合作项目的里程碑款项，将是公司2026年的主要财务增长点。 JAB-23E73的临床价值与开发前景 JAB-23E73是加科思基于诱导变构平台开发的创新型泛KRAS抑制剂，旨在靶向多种KRAS突变亚型。KRAS是人类最常见的突变致癌基因之一，占全部患者比例约23%。该产品目前正在中国和美国开展I期临床试验，并已观察到早期抗肿瘤活性信号。据加科思官方披露，截至2026年1月15日，中国一期试验共入组42例患者，在预测有效剂量范围内的13例胰腺癌患者中，客观缓解率为38.5%，疾病控制率为84.6%。2026年2月，JAB-23E73联合白蛋白结合型紫杉醇和吉西他滨用于KRAS突变胰腺癌一线治疗的Ib/III期临床试验已获得国家药监局药审中心批准。王印祥博士曾在接受采访时表示，通过与阿斯利康合作，加科思有望加快全球开发节奏，并同时推进多个临床试验。此前，公司难以在全球范围内全面铺开多适应证临床试验。结语从2025年12月协议签署到1亿美元首付款到账，仅用时三个月。这笔资金的意义不仅是账面上多了一笔现金，更重要的是验证了加科思"License out"商业模式的可行性——在成立之初，王印祥就将对外授权交易明确为核心商业模式，整个组织架构和资源配置都围绕此展开。如今，这一模式正在兑现它的价值。对于一家专注KRAS赛道的Biotech而言，来自阿斯利康的背书和资金支持，将帮助它在胰腺癌、非小细胞肺癌等多个KRAS突变相关实体瘤领域加速推进。而随着JAB-23E73早期临床数据的逐步读出，这场关于"不可成药"靶点的较量，才刚刚开始。封面来源：企业logo 声明：文章中的信息仅供一般参考之用，不可直接作为决策内容。蒲公英资讯 | 更懂制药人专注医药产业与行业技术；提供深度资讯、专业咨询、媒体宣传与资源链接；助力企业把握行业脉搏，链接产业价值。欢迎合作交流：孟女士 18810836617 蒲公英资讯 END 点击名片欢迎关注我们

2026-03-30

·雪球

创新药+出海：10家核心企业解析

前言：从“仿制药大国”到“创新药强国”，中国生物医药产业的转型之路，正伴随着“出海”的浪潮加速前行。曾经，中国药企的海外布局多停留在仿制药出口的初级阶段，而如今，越来越多具备核心研发实力的企业，带着自主创新的原研药、突破性技术，叩开了全球市场的大门，从“产品出海”迈向“技术出海”“品牌出海”的高阶阶段。在这条充满机遇与挑战的赛道上，有这样10家企业，它们深耕创新药研发，布局全球化布局，凭借差异化的管线优势、硬核的技术突破和灵活的海外合作模式，成为中国创新药出海的“主力军”。它们中，有龙头引领、全面开花的标杆企业，有聚焦特色、实现技术突围的黑马企业，也有深耕细分、加速追赶的潜力企业。今天，我们就一起来深度拆解这10家企业，看看它们如何以创新为帆、以出海为桨，书写中国生物医药的全球化篇章。当前，创新药出海已成为中国生物医药产业高质量发展的核心赛道，一批具备核心研发实力、全球化布局能力的企业脱颖而出。以下10家公司深度布局创新药研发与海外市场拓展，凭借差异化管线、核心技术突破及海外合作优势，成为“创新药+出海”赛道的核心参与者，具体解析如下：一、核心出海标杆企业（研发与商业化双领先）1.恒瑞医药作为国内创新药龙头，恒瑞医药以持续高额研发投入为根基，累计研发投入已超500亿元，2025年前三季度研发费用达49.45亿元，已在中国获批上市24款1类创新药和5款2类新药，同时拥有100多个自主创新产品在临床开发、400余项国内外临床试验正在推进。国际化进程全面提速，海外BD合作成果丰硕，2025年三季度达成3项海外BD授权，包括与GSK合作共同开发至多12款创新药物，潜在总金额约120亿美元，同时有5款创新药获得FDA孤儿药资格认定，多款研究成果亮相ESMO等国际顶尖学术会议，进一步扩大全球影响力，中高层中拥有海外或跨国药企经验者占比超30%，为全球化布局提供坚实支撑。2.百济神州聚焦肿瘤领域的全球化创新药企，自创立以来坚持国际化发展理念，已在六大洲组建超11000人团队，在美国纳斯达克、香港联交所和上交所科创板三地上市。拥有超过1100名科研人员，构建了覆盖血液肿瘤、实体肿瘤、免疫治疗和炎症三大领域的丰富管线，80%的商业化产品和在研管线覆盖全球80%的癌症种类。核心产品百悦泽（泽布替尼）已在70多个市场获批，全球超180000例患者接受治疗；百泽安（替雷利珠单抗）已在45个国际市场获批，全球超130万患者接受治疗。同时布局全球生产基地，在美国新泽西州、中国苏州和广州建有生产基地，符合FDA、NMPA、EMA的GMP标准，实现“研发-生产-商业化”全链条全球化覆盖。3.复星医药以创新研发与全球化为双引擎，2025年境外收入达129.77亿元，同比增长14.87%，创新药品收入98.93亿元，同比增长29.59%。持续深化创新药布局，2026年3月自研创新药FXS0683获批临床，聚焦血液系统恶性肿瘤领域，同时引进全球首个且唯一获批的磷吸收抑制剂万缇乐®（盐酸替那帕诺片）并实现商业上市。通过产学研融合强化创新实力，与中国药科大学签署战略合作协议，同时依托全球化布局，推动创新药在海外市场的落地，形成“自研+引进”双轮驱动、国内外协同发展的出海格局，海外市场影响力持续提升。二、技术突破型出海企业（聚焦特色管线与核心技术）4.百利天恒以双抗ADC为核心技术优势，创新实力获得国际巨头认可，2023年12月与百时美施贵宝（BMS）达成总额高达84亿美元的合作协议，授予BMS其核心产品BL-B01D1在中国以外地区的开发和商业化权利，刷新国产ADC药物出海授权纪录，该药物也成为首款成功出海的国产双抗ADC新药。目前BMS已在美国启动该药物一线晚期三阴性乳腺癌的II/III期临床试验及多项早期研究，公司在美国西雅图和中国成都布局研发中心，协同推进全球多中心临床试验，秉持“扎根中国、走向全球”的战略，致力于成为肿瘤用药领域具有全球领先优势的跨国药企。5.荣昌生物聚焦创新生物药研发，以双抗、ADC等核心技术为支撑，2026年1月与全球制药巨头艾伯维签署RC148的独家授权许可协议，艾伯维获得该药物大中华区以外地区的开发、生产和商业化独家权利，交易涉及6.5亿美元首付款及最高49.5亿美元的里程碑付款，彰显其研发实力获得国际顶级药企认可。RC148是自主研发的PD-1/VEGF双特异性抗体，临床数据表现优异，在ESMO-IO大会上公布的单药一线治疗非小细胞肺癌客观缓解率达61.9%，已获得中国突破性治疗药物资格认定及FDAII期临床批准，依托自主Hibody双功能抗体平台，持续推进创新药全球化布局，同时保留大中华区权益，兼顾本土与海外市场发展。6.科伦药业依托“三发驱动、创新增长”战略，在创新药领域重点布局肿瘤、自身免疫等重大疾病领域，旗下科伦博泰搭建了享誉国际的ADC研发平台，2022年与默沙东达成总金额超100亿美元的授权合作，奠定国内创新药研发第一方阵地位。核心产品佳泰莱®（TROP2ADC）、科泰莱®（全球首款鼻咽癌PD-L1单抗）陆续获批上市，多个创新药项目处于临床阶段，其中多个为全球多中心研究，与欧美合作伙伴携手布局全球临床，同时主导产品已批量出口至50多个国家和地区，在输液领域拥有全球影响力，形成“仿制药出海打底、创新药出海突破”的全球化格局。三、潜力成长型出海企业（聚焦细分赛道，加速海外突破）7.诺诚健华聚焦肿瘤与自身免疫性疾病领域，核心产品奥布替尼是全球首个进入Ⅲ期临床的中枢神经系统强渗透性BTK抑制剂，已在中国获批四个血液瘤适应症，其中三个纳入医保。2025年10月与美国ZenasBioPharma达成潜在总金额超20亿美元的全球授权合作，聚焦奥布替尼在多发性硬化症（MS）领域的开发及其他自身免疫性疾病管线，Zenas获得相关领域全球或区域独家权利，奥布替尼针对原发进展型多发性硬化症的全球Ⅲ期试验已启动，同时公司持续布局自身免疫性疾病领域全球前沿靶点，推动创新药出海实现重大突破。8.三生国健国内首批专注于抗体药物的创新药企，拥有研产销一体化成熟平台，2025年5月与辉瑞达成关于PD-1/VEGF双抗SSGJ-707的授权协议，辉瑞获得该药物全球（不包括中国内地）的独家开发、生产、商业化权利，交易涉及12.5亿美元首付款及最高48亿美元的里程碑付款。SSGJ-707基于CLF2专利平台开发，II期临床数据优异，已获得中国突破性治疗药物认定及FDAIND批准，目前多项适应症处于临床II、III期阶段，此次合作标志着公司双抗研发平台获得国际认可，加速推动创新药全球化落地。9.艾力斯专注于肿瘤治疗领域的创新型制药企业，2020年在科创板上市，核心布局KRASG12C等关键靶点。2024年8月与加科思药业签订许可协议，获得KRASG12C靶向药物戈来雷塞及SHP2抑制剂在中国地区的独家开发和商业化权利，戈来雷塞已在中国、美国及欧洲多国启动多项晚期实体瘤临床试验，其胰腺癌适应症在美国和欧洲获得孤儿药认定，在中国被纳入突破性治疗药物认定程序。公司组建专业化营销团队，同时积极推动核心产品的全球化临床布局，逐步实现创新药出海突破，聚焦肿瘤领域打造具有全球竞争力的产品管线。10.百奥泰全球性生物制药企业，聚焦创新药与生物类似药研发，产品覆盖肿瘤、自身免疫性疾病等领域，多款药物实现中美欧等多地获批上市，其中托珠单抗成为首个由中国药企研发、生产且获得美国FDA批准上市的单克隆抗体药物。2025年以来，核心产品乌司奴单抗相继获得美国FDA、欧盟委员会、英国MHRA上市批准，公司与吉瑞医药签署协议，授权其在欧盟、英国等市场的商业化，同时推动多款候选药物进入后期临床试验，聚焦PD-1后时代肿瘤免疫治疗和ADC靶向药物开发，持续拓展全球生物类似药与创新药业务布局，海外市场覆盖持续扩大。总结：创新为核，出海为翼，中国药企的全球化未来可期回望中国创新药出海的历程，从早期的艰难探索，到如今的多点开花，这10家企业的成长与突破，正是中国生物医药产业崛起的缩影。它们或许所处赛道不同、发展阶段各异，但都有一个共同的特质——以创新为根本，以全球化为目标，在核心技术上持续深耕，在海外布局上稳步推进。恒瑞、百济神州、复星医药等标杆企业，凭借全链条布局和强大的商业化能力，引领中国创新药出海走向成熟；百利天恒、荣昌生物、科伦药业等技术型企业，以双抗、ADC等特色技术为突破口，实现了国产创新药的高端出海；诺诚健华、三生国健等潜力企业，聚焦细分赛道，凭借差异化管线逐步打开全球市场。当然，创新药出海之路从来不是一帆风顺的，面临着海外临床试验壁垒、市场竞争加剧、合规要求严苛等诸多挑战。但我们可以看到，中国药企正以更成熟的姿态、更硬核的实力，应对这些挑战——从自主研发到海外合作，从产品输出到技术授权，中国创新药的全球话语权正在逐步提升。未来，随着研发投入的持续加大、核心技术的不断突破，相信这10家企业，以及更多中国创新药企，将继续扛起“创新+出海”的大旗，推动更多国产原研药走向全球，让中国生物医药产业真正实现从“跟跑”向“并跑”“领跑”的跨越，为全球患者带来更多中国方案、中国力量。

100 项与枸橼酸格来雷塞相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
KRAS G12C突变非小细胞肺癌	中国	上海艾力斯医药科技股份有限公司	2025-05-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
KRAS G12C突变非鳞状非小细胞肺癌	临床3期	中国	北京加科思新药研发有限公司	2024-07-18
KRAS p.G12C突变胰腺癌	临床2期	中国	北京加科思新药研发有限公司	2023-10-16
胰腺导管癌	临床2期	中国	上海艾力斯医药科技股份有限公司	2022-04-14
晚期结直肠腺癌	临床2期	中国	上海艾力斯医药科技股份有限公司	2022-02-17
KRAS p.G12C突变结直肠癌	临床2期	中国	上海艾力斯医药科技股份有限公司	2022-02-17
小肠癌复发	临床2期	中国	上海艾力斯医药科技股份有限公司	2022-02-17
阑尾肿瘤	临床2期	中国	北京加科思新药研发有限公司	2022-02-07
小肠癌	临床2期	中国	北京加科思新药研发有限公司	2022-02-07
非小细胞肺癌	临床2期	美国	北京加科思新药研发有限公司	2021-09-03
结直肠癌	临床2期	美国	北京加科思新药研发有限公司	2021-09-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05009329 \| NCT05194995 (JAB-21822-1002, Pubmed \| Lancet Gastroenterol Hepatol)	临床1/2期	KRASG12C mutation	91	Glecirasib 800 mg once daily	膚廠製淵顧憲鏇淵網鏇(齋壓鹽積網範簾積選艱) = 夢齋範遞衊鹽鬱鬱築獵壓夢觸憲鬱憲餘衊窪鏇 (鑰鹽蓋積構觸夢膚築鏇, 11 ~ 38) 更多	积极	2026-02-01
				Glecirasib 800 mg once daily + cetuximab	膚廠製淵顧憲鏇淵網鏇(齋壓鹽積網範簾積選艱) = 糧衊醖齋範膚築膚顧淵壓夢觸憲鬱憲餘衊窪鏇 (鑰鹽蓋積構觸夢膚築鏇, 35 ~ 65) 更多
NCT05009329 \| NCT05194995 (Pubmed \| Lancet Gastroenterol Hepatol) 人工标引	临床1/2期	KRAS G12C突变结直肠癌 KRAS G12C	91	Glecirasib 800 mg once daily	鹽鬱範齋壓蓋淵襯獵鏇(簾觸範遞遞網繭鹹糧觸) = 餘鹽衊獵壓憲鑰醖壓獵襯觸範襯鹽獵願憲積鹽 (鹽顧觸鏇網淵壓淵鑰艱, 11 ~ 38) 更多	积极	2025-12-01
				Glecirasib 800 mg once daily + Cetuximab	鹽鬱範齋壓蓋淵襯獵鏇(簾觸範遞遞網繭鹹糧觸) = 鹽襯網範網衊簾艱鹽構襯觸範襯鹽獵願憲積鹽 (鹽顧觸鏇網淵壓淵鑰艱, 35 ~ 65) 更多
NCT05009329 \| NCT05194995 (JAB-21822-1002, Pubmed \| Lancet Gastroenterol Hepatol)	临床1/2期	KRASG12C mutation	91	Glecirasib 800 mg once daily	壓鹽餘鑰壓餘艱壓鬱齋(製選構憲蓋鏇積構醖糧) = 糧淵蓋鏇築衊鹽餘遞鹽鹹鹽簾製蓋網淵築願糧 (繭鬱獵膚遞夢齋鬱膚構, 11 ~ 38) 更多	积极	2025-12-01
				Glecirasib 800 mg once daily + cetuximab	壓鹽餘鑰壓餘艱壓鬱齋(製選構憲蓋鏇積構醖糧) = 網膚構糧選選夢繭夢簾鹹鹽簾製蓋網淵築願糧 (繭鬱獵膚遞夢齋鬱膚構, 35 ~ 65) 更多
NCT05009329 \| NCT05002270 (Pubmed \| Cancer Commun (Lond))	临床1/2期	KRAS G12C突变的实体瘤 KRAS G12C mutation	54	Glecirasib	憲網鑰廠窪築繭膚獵鹽(糧繭製構醖廠蓋鑰壓築) = 鹹獵願積鏇醖齋範夢齋築觸壓顧鏇壓衊築廠願 (鑰繭鑰願顧鹹夢齋構網, 36.8 ~ 64.9) 更多	积极	2025-11-01
				Glecirasib (PDAC)	憲網鑰廠窪築繭膚獵鹽(糧繭製構醖廠蓋鑰壓築) = 淵鏇範願選鹹蓋鏇蓋範築觸壓顧鏇壓衊築廠願 (鑰繭鑰願顧鹹夢齋構網, 29.1 ~ 65.3) 更多
NEWS 人工标引	临床2期	KRAS G12C突变非小细胞肺癌一线 KRAS G12C	-	Glecirasib	選夢築願鏇鹽淵窪獵鑰(夢顧憲蓋淵糧鹹遞顧構) = 顧鬱憲齋夢醖鏇繭網壓顧觸壓鹹製壓鹽積壓遞 (鹽遞製願鬱範獵觸選遞 ) 更多	积极	2025-07-16
				Sotorasib	選夢築願鏇鹽淵窪獵鑰(夢顧憲蓋淵糧鹹遞顧構) = 鬱衊餘鏇範網遞糧觸醖顧觸壓鹹製壓鹽積壓遞 (鹽遞製願鬱範獵觸選遞 ) 更多
NCT05009329 \| NCT05194995 (ASCO_GI2025) 人工标引	临床1/2期	KRAS G12C突变结直肠癌 KRAS G12C	44	Glecirasib 800mg QD	顧構醖鹹願獵鑰選網遞(願製繭窪艱遞獵鬱繭淵) = 憲齋願醖網獵壓憲夢壓顧鏇窪鹽艱醖蓋網顧壓 (糧鹹願鬱選齋構壓鏇範 ) 更多	积极	2025-01-23
				Glecirasib 800mg QD + Cetuximab	顧構醖鹹願獵鑰選網遞(願製繭窪艱遞獵鬱繭淵) = 廠顧餘憲積網衊範鏇網顧鏇窪鹽艱醖蓋網顧壓 (糧鹹願鬱選齋構壓鏇範 ) 更多
NCT05009329 (Pubmed) 人工标引	临床2期	KRAS G12C突变非小细胞肺癌 KRAS G12C	119	Glecirasib 800 mg daily	製積簾艱齋鑰襯齋網鑰(壓鑰簾醖壓齋膚鬱齋願) = 遞齋鑰簾獵鏇餘選鏇醖糧淵顧鬱繭糧構憲憲餘 (網鹽繭觸齋膚憲構鏇獵, 38.5 ~ 57.3) 更多	积极	2025-01-06
NCT05288205 (ESMO2024) 人工标引	临床1/2期	KRAS G12C突变非小细胞肺癌一线 KRAS G12C \| PD-L1	102	Glecirasib plus JAB-3312	觸鹽鬱淵遞簾製壓構窪(觸夢顧齋獵製鬱遞糧餘) = 壓願壓膚顧製遞餘壓餘顧獵艱積構顧遞夢選繭 (襯鏇艱觸艱蓋鏇範簾廠 ) 更多	积极	2024-09-14
				Glecirasib plus JAB-3312 (PD-L1 TPS≥50%)	觸鹽鬱淵遞簾製壓構窪(觸夢顧齋獵製鬱遞糧餘) = 夢淵築築願餘鬱顧壓獵顧獵艱積構顧遞夢選繭 (襯鏇艱觸艱蓋鏇範簾廠 ) 更多
NCT05288205 (PRNewswire) 人工标引	临床1/2期	KRAS G12C突变非小细胞肺癌一线 KRAS G12C	194	JAB-21822+JAB-3312	艱遞鏇鬱願顧衊醖繭顧(選鹹齋簾鹹膚願壓構蓋) = 齋糧襯窪築醖衊鑰醖觸膚顧獵築鬱簾繭願積築 (願選鹹蓋鑰遞廠構網窪 )	积极	2024-06-01
				JAB-21822+JAB-3312 (frontline)	廠衊範壓觸衊襯願窪壓(築窪選觸齋獵衊齋艱繭) = 構顧鬱鏇夢憲願願鹽襯鏇觸夢壓鏇餘齋願醖願 (製襯壓憲餘齋衊膚襯製 ) 更多
NCT05288205 (ASCO2024) 人工标引	临床1/2期	KRAS G12C突变的实体瘤 KRAS G12C	179	Glecirasib 800 mg	糧醖獵製簾鹽夢淵鹽鏇(構憲淵蓋遞醖獵繭壓簾) = 繭壓衊獵蓋衊鹹壓艱觸餘鏇獵鑰鑰遞製簾選衊 (淵鹽網壓顧顧製遞獵鑰 ) 更多	积极	2024-05-24